Cargando…
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes
Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in thi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237274/ https://www.ncbi.nlm.nih.gov/pubmed/28086951 http://dx.doi.org/10.1186/s12933-016-0489-z |
_version_ | 1782495502193917952 |
---|---|
author | Habibi, Javad Aroor, Annayya R. Sowers, James R. Jia, Guanghong Hayden, Melvin R. Garro, Mona Barron, Brady Mayoux, Eric Rector, R. Scott Whaley-Connell, Adam DeMarco, Vincent G. |
author_facet | Habibi, Javad Aroor, Annayya R. Sowers, James R. Jia, Guanghong Hayden, Melvin R. Garro, Mona Barron, Brady Mayoux, Eric Rector, R. Scott Whaley-Connell, Adam DeMarco, Vincent G. |
author_sort | Habibi, Javad |
collection | PubMed |
description | Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in this population. Recent clinical data suggest sodium glucose transporter-2 (SGLT2) inhibition reduces CVD events in diabetic individuals, but the mechanisms of this CVD protection are unknown. To determine whether targeting SGLT2 improves diastolic relaxation, we utilized empagliflozin (EMPA) in female db/db mice. Eleven week old female db/db mice were fed normal mouse chow, with or without EMPA, for 5 weeks. Blood pressure (BP), HbA1c and fasting glucose were significantly increased in untreated db/db mice (DbC) (P < 0.01). EMPA treatment (DbE) improved glycemic indices (P < 0.05), but not BP (P > 0.05). At baseline, DbC and DbE had already established impaired diastolic relaxation as indicated by impaired septal wall motion (>tissue Doppler derived E′/A′ ratio) and increased left ventricular (LV) filling pressure (<E/E′ ratio). Although these abnormalities persisted throughout the study period in DbC, diastolic function improved with EMPA treatment. In DbC, myocardial fibrosis was accompanied by increased expression of profibrotic/prohypertrophic proteins, serum/glucocorticoid regulated kinase 1 (SGK1) and the epithelial sodium channel (ENaC), and the development of these abnormalities were reduced with EMPA. DbC exhibited eccentric LV hypertrophy that was slightly improved by EMPA, indicated by a reduction in cardiomyocyte cross sectional area. In summary, EMPA improved glycemic indices along with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which occurred in the absence of any changes in BP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-016-0489-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5237274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52372742017-01-18 Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes Habibi, Javad Aroor, Annayya R. Sowers, James R. Jia, Guanghong Hayden, Melvin R. Garro, Mona Barron, Brady Mayoux, Eric Rector, R. Scott Whaley-Connell, Adam DeMarco, Vincent G. Cardiovasc Diabetol Original Investigation Obese and diabetic individuals are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction. The impairments in diastolic relaxation are especially pronounced in obese and diabetic women and predict future cardiovascular disease (CVD) events in this population. Recent clinical data suggest sodium glucose transporter-2 (SGLT2) inhibition reduces CVD events in diabetic individuals, but the mechanisms of this CVD protection are unknown. To determine whether targeting SGLT2 improves diastolic relaxation, we utilized empagliflozin (EMPA) in female db/db mice. Eleven week old female db/db mice were fed normal mouse chow, with or without EMPA, for 5 weeks. Blood pressure (BP), HbA1c and fasting glucose were significantly increased in untreated db/db mice (DbC) (P < 0.01). EMPA treatment (DbE) improved glycemic indices (P < 0.05), but not BP (P > 0.05). At baseline, DbC and DbE had already established impaired diastolic relaxation as indicated by impaired septal wall motion (>tissue Doppler derived E′/A′ ratio) and increased left ventricular (LV) filling pressure (<E/E′ ratio). Although these abnormalities persisted throughout the study period in DbC, diastolic function improved with EMPA treatment. In DbC, myocardial fibrosis was accompanied by increased expression of profibrotic/prohypertrophic proteins, serum/glucocorticoid regulated kinase 1 (SGK1) and the epithelial sodium channel (ENaC), and the development of these abnormalities were reduced with EMPA. DbC exhibited eccentric LV hypertrophy that was slightly improved by EMPA, indicated by a reduction in cardiomyocyte cross sectional area. In summary, EMPA improved glycemic indices along with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which occurred in the absence of any changes in BP. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12933-016-0489-z) contains supplementary material, which is available to authorized users. BioMed Central 2017-01-13 /pmc/articles/PMC5237274/ /pubmed/28086951 http://dx.doi.org/10.1186/s12933-016-0489-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Habibi, Javad Aroor, Annayya R. Sowers, James R. Jia, Guanghong Hayden, Melvin R. Garro, Mona Barron, Brady Mayoux, Eric Rector, R. Scott Whaley-Connell, Adam DeMarco, Vincent G. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
title | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
title_full | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
title_fullStr | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
title_full_unstemmed | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
title_short | Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
title_sort | sodium glucose transporter 2 (sglt2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237274/ https://www.ncbi.nlm.nih.gov/pubmed/28086951 http://dx.doi.org/10.1186/s12933-016-0489-z |
work_keys_str_mv | AT habibijavad sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT aroorannayyar sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT sowersjamesr sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT jiaguanghong sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT haydenmelvinr sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT garromona sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT barronbrady sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT mayouxeric sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT rectorrscott sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT whaleyconnelladam sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes AT demarcovincentg sodiumglucosetransporter2sglt2inhibitionwithempagliflozinimprovescardiacdiastolicfunctioninafemalerodentmodelofdiabetes |